MorphoSys AG (ETR:MOR)‘s stock had its “neutral” rating restated by equities research analysts at J P Morgan Chase & Co in a report released on Wednesday.

Other research analysts also recently issued research reports about the stock. Berenberg Bank set a €68.00 ($80.95) target price on shares of MorphoSys AG and gave the company a “buy” rating in a research report on Wednesday, August 16th. Commerzbank Ag set a €76.00 ($90.48) target price on shares of MorphoSys AG and gave the company a “buy” rating in a research report on Monday, July 24th. Goldman Sachs Group, Inc. (The) set a €55.00 ($65.48) target price on shares of MorphoSys AG and gave the company a “neutral” rating in a research report on Monday, July 24th. Independent Research GmbH set a €77.00 ($91.67) target price on shares of MorphoSys AG and gave the company a “buy” rating in a research report on Monday, July 17th. Finally, Deutsche Bank AG set a €90.00 ($107.14) target price on shares of MorphoSys AG and gave the company a “buy” rating in a research report on Tuesday, August 1st. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of €70.38 ($83.78).

Shares of MorphoSys AG (ETR MOR) traded down 0.76% during midday trading on Wednesday, reaching €65.25. 4,295 shares of the company’s stock traded hands. The stock has a 50-day moving average price of €60.15 and a 200-day moving average price of €59.03. The stock’s market cap is €1.89 billion. MorphoSys AG has a 52-week low of €35.72 and a 52-week high of €70.90.

TRADEMARK VIOLATION NOTICE: “MorphoSys AG (MOR) Stock Rating Reaffirmed by J P Morgan Chase & Co” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/10/morphosys-ag-mor-stock-rating-reaffirmed-by-j-p-morgan-chase-co.html.

MorphoSys AG Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.